Global Community

At A$7.072 per share, Treasury Wine Estates (ASX: TWE) appears reasonably valued, although the assessment relies on earnings recovering during the second half of FY26. TWE reported first-half revenue of A$1.30 billion, EBITS of A$236.4 million and underlying earnings of 15.9 cents per share.Read more

LVMH is the world’s largest luxury group — but the market isn’t treating it like one right now. The numbers tell a very clear story: the stock is priced as if the company’s golden era is over , while the fundamentals suggest the opposite.Read more

I. Executive Summary and Signal The central thesis currently priced into the market is not the company's weakness, but the erosion of its monopoly.Read more

At A$36.602 per share, Woodside Energy Group (ASX: WDS) appears reasonably valued based on its existing operations and near-term production growth. Woodside reports in US dollars and recorded 2025 operating revenue of US$12.9 billion, underlying profit of US$2.65 billion and earnings of US$1.43 per share.Read more

Kartoon Studios announced approximately $78.5 million in litigation settlements—an enormous figure beside the company’s recent market value. For a moment, the story sounds easy: a small company wins a large settlement, receives the money, and the stock catches up.Read more

ASML makes the one type of chipmaking machine that advanced chips can’t be built without, putting it at the center of the AI and high-end electronics boom. But that power comes with big dependencies—politics, a few key customers, and whether the next wave of machines is worth the cost.Read more

Fortinet builds much of its security gear in-house and runs it all on one system, which can make it cheaper, faster, and easier for customers to manage. But its reliance on hardware sales and the fight for cloud customers could test whether this edge holds up as the market shifts.Read more

Vistra looks like a quiet backbone behind the boom in data centers, with long-term power deals tied to household-name tech companies. The catch is that regulators, shifting tech spending, and power-market surprises could quickly change how safe those deals and returns really are.Read more

Zevra shifts from a research-heavy biotech into a commercial company after winning approval for a first-of-its-kind treatment for an ultra-rare, serious disease. A cash boost and ongoing royalty income could help fund the launch and reduce the need to raise money, but execution still matters.Read more